title: The effects of bestatin on humoral response to sheep erythrocytes in non-treated and cyclophosphamide-immunocompromised mice.
abstract: The effects of bestatin on humoral immune response to sheep erythrocytes (SRBC) and restoration of the response impaired by a single cyclophosphamide dose (350 mg/kg) were tested on mice. Bestatin (at doses of 10, 1, and 0.1 mg/kg) was administered intraperitoneally (i.p.) 5 or 10 times. The pharmacological immunosuppression was induced by a single i.p. injection of cyclophosphamide (350 mg/kg) administered 24 h before the first bestatin dose. The mice were immunized i.p. with SRBC 24 h after the last dose of bestatin. It was found that multiple administration of bestatin at all three doses potentiated the humoral response to SRBC in non-treated mice, resulting in an increased number of plaque-forming cells (PFC) and 2-mercaptoethanol (2-ME)-resistant anti-SRBC antibodies. However, five times administration of bestatin at the doses under investigation caused further decreases in total anti-SRBC hemagglutinins. A single injection of cyclophosphamide (350 mg/kg) suppressed humoral response of mice to the antigen. Administration of bestatin after pharmacological immunosuppression partially prevented the suppressive action of cyclophosphamide in the in vivo model of the humoral immune response to SRBC. The protective action of bestatin was both dose- and schedule-dependent. Ten times' exposure to a bestatin dose of 0.1 mg/kg after a high cyclophosphamide dose partially reduced the suppressive effect of this drug on humoral response of SRBC-immunized mice, increasing PFC on days 4 and 7 after immunization, which coincided with restored ability of the lymphocytes to produce the 2-ME-resistant hemagglutinins on day 7 and the total anti-SRBC hemagglutinins on day 14 after priming.
authors.affiliation: Department of Biochemistry, Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Wrocław, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Lis
authors.forename: Marianna
authors.initials: M
authors.lastname: Szczypka
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Suszko
authors.forename: Bożena
authors.initials: B
authors.lastname: Obmińska-Mrukowicz
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D003520:Cyclophosphamide / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects* / Q000276:immunology*; D005260:Female; D006388:Hemagglutinins / Q000276:immunology; D056724:Immunity, Humoral / Q000187:drug effects; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D008623:Mercaptoethanol / Q000276:immunology / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D012756:Sheep
chemical_list: D000906:Antibodies; D006388:Hemagglutinins; D008623:Mercaptoethanol; D003520:Cyclophosphamide; D007930:Leucine; C012211:ubenimex